FDA Accepts Application for Merck's KEYTRUDA® as Adjuvant Therapy for Stage IB -IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection Life Science Investing
AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab in Patients with Relapsed/Refractory Large B-cell Lymphoma at the European Hematology Association Annual Congress Pharmaceutical Investing
AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients Pharmaceutical Investing
New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment Pharmaceutical Investing
Viemed Healthcare Announces Voting Results From Its Annual General Meeting of Shareholders Medical Device Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
